Roivant acquires Alzheimer’s drug candidate from GlaxoSmithKline

Company plans to commence Phase 3 clinical trials of SB742457 in 2015

Register for free to listen to this article
Listen with Speechify
HAMILTON, Bermuda—Roivant Neurosciences Ltd., a biopharmaceutical company dedicated to the development and commercialization of late-stage drug candidates for neurologic diseases, has entered into an agreement with GlaxoSmithKline for the acquisition of SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders. GSK has conducted thirteen clinical studies of SB742457 involving more than 1,250 healthy subjects and Alzheimer's disease patients. The results of these studies provide strong evidence that SB742457 holds promise for patients with mild-to-moderate Alzheimer's disease.
"This transaction represents a foundational late-stage clinical asset for Roivant," stated Vivek Ramaswamy, founder and director of Roivant Sciences Ltd. and CEO of Roivant Sciences, Inc. "Our organization is fully committed to building on the research already completed by GSK and advancing a new therapeutic option for Alzheimer's disease, a debilitating and deadly disease that affects millions of patients and their families."
Roivant intends to meet with the U.S. Food and Drug Administration (FDA) in the first half of 2015 to confirm the regulatory requirements for the continued development of SB742457 for the treatment of the signs and symptoms of mild-to-moderate Alzheimer's disease. Roivant may also explore the clinical development of SB742457 for other neurological disorders for which there are limited or no therapeutic options.
"Despite the large number of clinical trials in Alzheimer's disease and related disorders during the past decade, there have been no new drugs approved in that period," stated Dr. Lawrence Friedhoff, senior vice president, research and development of Roivant Sciences, Inc. and the development team leader for Aricept® (donepezil hydrochloride), the drug most commonly used for the treatment of Alzheimer's disease. "As we advance SB742457 into Phase 3 pivotal studies in 2015, we hope and expect that these clinical trials will support the approval of a new therapeutic option for patients."
Alzheimer's disease is a progressive, neurodegenerative disorder characterized by problems with memory, thinking and behavior that eventually become severe enough to affect daily tasks. An estimated 5.2 million people in the United States are currently living with Alzheimer's disease. Alzheimer's disease is the fifth leading cause of death in the United States among those aged 65 and older, and was reported as an underlying cause of death for more than 83,000 Americans in 2010. The cost of caring for patients with Alzheimer's disease places a significant burden on health services.
SB742457 is a novel and potent 5-HT6 receptor antagonist that is being developed as an oral treatment for subjects with mild-to-moderate Alzheimer's disease. SB742457 improves cognition in preclinical models, and preliminary preclinical data suggest a potential additive or synergistic effect when 5-HT6 antagonists are added to acetylcholinesterase inhibitors, one of the two classes of drugs approved by the FDA for the treatment of Alzheimer's disease. Four Phase 2 studies of SB742457 in subjects with mild-to-moderate Alzheimer's disease have been completed, including three monotherapy studies and one adjunctive therapy study in patients already taking an acetylcholinesterase inhibitor, Aricept (donepezil hydrochloride). SB742457 was generally safe and well-tolerated in all Phase 2 studies. The results of these studies provide strong evidence that SB742457 holds promise for patients with mild-to-moderate Alzheimer's disease.  Aricept is a trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
Roivant Neurosciences Ltd. is a wholly-owned subsidiary of Roivant Sciences Ltd., a biopharmaceutical firm focused on the late-stage clinical development and commercialization of nonstrategic, deprioritized or under-resourced drug candidates. Backed by a global multi-strategy investment firm and an international specialty pharmaceutical company, Roivant Sciences uses its capital and in-house drug development expertise to move programs forward across a variety of pharmaceutical indications.
Roivant Sciences selectively evaluates regional or global opportunities across all therapeutic areas, mechanisms of action and routes of administration, with a special emphasis on areas of high unmet medical need, including rare diseases. Roivant will consider all levels of innovativeness while seeking to identify drug candidates whose potential may be underappreciated.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue